MTN-020-ASPIRE A Vaginal Ring Containing Dapivirine for HIV-1 PrEP - PowerPoint PPT Presentation

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Background Study Design: ASPIRE • Background : Randomized, double-blind, phase 3, placebo-controlled trial of a dapivirine-containing vaginal ring changed every 4 weeks as compared to a placebo ring for HIV-1 prevention for women Placebo Ring at multiple sites in Malawi, South Africa, Uganda (n = 1,316) and Zimbabwe • Inclusion Criteria (2,629 enrolled) - 18-45 years of age - HIV seronegative Dapivirine Ring - Sexually active (n = 1,313) - Nonpregnant • Treatment Arms: - Dapivirine 25 mg vaginal ring, changed monthly - Placebo vaginal ring, changed monthly Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results Number of New HIV Infections (All Sites) 150 P = 0.046 Number of HIV Infections 125 ⇓ 27% 97 100 71 75 50 25 0 Placebo ring Dapivirine ring Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results Number of New HIV Infections (Excluding 2 Sites with Poor Retention) 150 P = 0.007 Number of HIV Infections 125 ⇓ 37% 100 85 75 54 50 25 0 Placebo ring Dapivirine ring Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results Incidence Rate for New HIV Infections 10 Incidence per 100 person-years P = 0.046 8 ⇓ 27% 6 4.5 4 3.3 2 0 Placebo ring Dapivirine ring Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results Relative Reduction, by Age Group 80 61 %Relative Reduction 60 40 27 20 10 0 Age ≤25 Overall Age >25 Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Results Reduction in HIV Incidence Comparing Age Groups Reduction in HIV Incidence by Age Groups in ASPIRE HIV Protection (Reduction in Incidence Comparing Dapivirine Ring to Placebo) Subgroup Analysis <25 years-old 10% >25 years-old *61% Post-hoc Analysis 18-21 years-old 27% 21-27 years-old *56% 27-45 years-old *51% *Improved HIV protection in older age groups correlated with increased markers of adherence Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

A Vaginal Ring Containing Dapivirine for HIV-1 PrEP MTN-020-ASPIRE Study: Conclusions Conclusions : “ A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.“ Source: Baeten JM, et al. N Engl J Med. 2016;375:2121-32.

Acknowledgment The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program. The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.